Summit Therapeutics Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Summit Therapeutics Inc. (SMMT) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$752.86 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-23
- Summit Therapeutics Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$752.86M.
- Summit Therapeutics Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$22.27M.
- Summit Therapeutics Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$115.12M.
- Summit Therapeutics Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$31.91M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 11 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 11 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | -$752.86M 10-K · filed 2026-02-23 | |||
| 2024-12-31 | -$22.27M 10-K · filed 2026-02-23 | |||
| 2023-12-31 | -$115.12M 10-K · filed 2026-02-23 | |||
| 2022-12-31 | -$31.91M 10-K · filed 2025-02-24 | |||
| 2021-12-31 | -$16.36M 10-K · filed 2023-03-09 | |||
| 2020-12-31 | -$1.71M 10-K/A · filed 2022-12-21 | |||
| 2019-12-31 | $133.00K 10-K · filed 2021-03-31 | -$29.22M 8-K · filed 2020-09-29 | ||
| 2019-01-31 | $1.53M 10-K · filed 2021-03-31 | $7.55M 8-K · filed 2020-09-29 | ||
| 2018-01-31 | -$26.16M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |